Venetoclax (Venclyxto®) for Acute Myeloid Leukaemia. HTA ID: 22001

Assessment Status NCPE assessment ongoing
HTA ID 22001
Drug Venetoclax
Brand Venclyxto®
Indication In combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
Assessment Process
Rapid review commissioned 05/01/2022
Rapid review completed 01/02/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with a hypomethylating agent compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 23/02/2022
Pre-submission consultation with Applicant 05/07/2022
Full submission received from Applicant 13/10/2022